Medicine & Life Sciences
Ovarian Neoplasms
100%
Poly(ADP-ribose) Polymerase Inhibitors
41%
Neoplasms
36%
veliparib
31%
Platinum
29%
Ovarian Epithelial Carcinoma
25%
gemcitabine
24%
Paclitaxel
22%
niraparib
20%
Drug Therapy
18%
Survival
16%
tanespimycin
15%
Heterografts
14%
Carboplatin
14%
Therapeutics
14%
Letrozole
13%
Somatomedin Receptors
13%
Triple Negative Breast Neoplasms
12%
rucaparib
11%
Homologous Recombination
11%
Progression-Free Survival
10%
Topotecan
10%
(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone
10%
BMS 536924
10%
OSI 027
10%
Mechanistic Target of Rapamycin Complex 2
10%
Group III Phospholipases A2
10%
AMG 479
10%
Mutation
10%
Carcinoma
10%
Clinical Trials
9%
Estrogen Receptors
9%
MDX-H210 antibody
9%
Nicotinamide N-Methyltransferase
8%
protein kinase C lambda
8%
ribociclib
8%
Fallopian Tubes
8%
navitoclax
8%
Apoptosis
8%
Folate Receptor 1
8%
Puma
7%
Auranofin
7%
TOR Serine-Threonine Kinases
7%
Emergencies
7%
olaparib
7%
Placebos
7%
Epithelioid Hemangioendothelioma
7%
Loratadine
7%
Bevacizumab
7%
Bispecific Antibodies
7%